Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.48 |
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672881 | 0.90 | ALK (0.55) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12797095 | 0.85 | JAK3 (0.53) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12797316 | 0.85 | JAK3 (0.49) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12797072 | 0.84 | JAK3 (0.52) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12797065 | 0.84 | IGF1R (0.52) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL671464 | 0.84 | JAK3 (0.52) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12796231 | 0.84 | JAK3 (0.52) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL1662508 | 0.84 | JAK3 (0.54) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL12797347 | 0.83 | JAK3 (0.47) | JAK3JAK2JAK1TYK2ALK | |
| SCHEMBL15122444 | 0.83 | IGF1R (0.54) | JAK3JAK2JAK1TYK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011156698-A2 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | JAK3 82/4885JAK2 217/4885JAK1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.